Abstract
The purposes of this study are to investigate medical resource utilization and medical costs of Korean rheumatoid arthritis (RA) patients and to analyze predictors in relation to medical costs. National claims data on medical treatment were analyzed for the 151,472 RA patients in 2009. For outpatients, the mean annual number of visits was 32.5, and the mean annual total outpatient care costs were 2.0 million KRW (US$1,594) per patient. On the other hand, the mean annual length of stay of inpatients was 22.2 days, and the mean annual total inpatient care costs were 3.8 million KRW (US$3,013). Average annual total medical costs per patient for all of the RA patients were 2.9 million KRW (US$2,310). Total medical costs consisted of 26.1% outpatients’ costs, 25.4% inpatient, and 48.6% medication costs, making medication costs a predominant cost driver. In the multiple regression analysis, biologic use was an important cost factor in relation to the annual total medical costs. This study provides information on the cost of illness of RA with the population-based representative RA patients in Korea, which had not been reported until now.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cooper NJ (2000) Economic burden of rheumatoid arthritis: a systematic review. Rheumatol (Oxford) 39(1):28–33
Kvien TK (2004) Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22(2 Suppl 1):1–12
Lundkvist J, Kastang F, Kobelt G (2008) The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 8(Suppl 2):S49–S60
Lajas C, Abasolo L, Bellajdel B, Hernandez-Garcia C, Carmona L, Vargas E, Lazaro P, Jover JA (2003) Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 49(1):64–70
Michaud K, Messer J, Choi HK, Wolfe F (2003) Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 48(10):2750–2762
Ruof J, Hulsemann JL, Mittendorf T, Handelmann S, von der Schulenburg JM, Zeidler H, Merkesdal S (2003) Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer’s data sources. Ann Rheum Dis 62(6):544–549
Guillemin F, Durieux S, Daures JP, Lafuma A, Saraux A, Sibilia J, Bourgeois P, Sany J (2004) Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists. J Rheumatol 31(7):1297–1304
Verstappen SM, Verkleij H, Bijlsma JW, Buskens E, Kruize AA, Heurkens AH, Van Der Veen MJ, Jacobs JW (2004) Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann Rheum Dis 63(7):817–824
Huscher D, Merkesdal S, Thiele K, Zeidler H, Schneider M, Zink A (2006) Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 65(9):1175–1183
Jacobsson LT, Lindroth Y, Marsal L, Juran E, Bergstrom U, Kobelt G (2007) Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmo, Sweden. Scand J Rheumatol 36(3):179–183
Kobelt G, Woronoff AS, Richard B, Peeters P, Sany J (2008) Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the eco-pr study. Jt Bone Spine 75(4):408–415
Lubeck DP (2001) A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings. Pharmacoeconomics 19(8):811–818
Rosery H, Bergemann R, Maxion-Bergemann S (2005) International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. Pharmacoeconomics 23(3):243–257
Kilian R, Matschinger H, Löeffler W, Roick C, Angermeyer MC (2002) A comparison of methods to handle skew distributed cost variables in the analysis of the resource consumption in schizophrenia treatment. J Ment Health Policy Econ 5(1):21–31
Hulsemann JL, Ruof J, Zeidler H, Mittendorf T (2006) Costs in rheumatology: results and lessons learned from the ‘Hannover costing study’. Rheumatol Int 26(8):704–711
Acknowledgments
This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (A102065).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kwon, JM., Cho, SK., Kim, JH. et al. Medical costs for Korean patients with rheumatoid arthritis based on the national claims database. Rheumatol Int 32, 2893–2899 (2012). https://doi.org/10.1007/s00296-011-2117-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-011-2117-2